Isomorphic Labs banked €1,930M ($2.1bn) Series B funding to accelerate its biological research and drug discovery efforts. The round was led by Thrive Capital and saw participation from the UK Sovereign AI fund, Abu Dhabi’s MGX, GV, and Temasek. This latest injection of capital follows a $600m raise secured roughly one year ago.
The London-based company is building a drug discovery platform by applying its sister company’s AlphaFold technology to model the structure of proteins. By using these AI systems, Isomorphic Labs aims to predict how drugs interact with the human body, significantly reducing the time and cost required for traditional pharmaceutical development. The business operates with a specialised workforce of chemists, pharmacologists, and biologists to bridge the gap between machine learning and life sciences.
Originally spun out from Google DeepMind in 2021, the company maintains close ties to its research roots while operating as a distinct commercial entity. It has already secured high-profile partnerships with pharmaceutical giants Eli Lilly and Novartis. According to company leadership, the firm has recently commenced pre-clinical trials for several proposed drug candidates.
The scale of this raise reinforces the UK's position as a primary hub for sovereign-backed deeptech, as European founders increasingly look toward massive late-stage rounds to compete with well-funded US counterparts.
Originally reported by Sifted.